Drs. George Martin and Ted Rosen talk candidly about why JAK inhibitors are important in the treatment of atopic dermatitis (AD), when dermatologists should consider using them, and how to safely mitigate risks and side effects while effectively treating AD patients with these powerful, “revolutionary” medications.
0:50 – The role of JAKs in AD
4:50 – JAK nuances
9:13 – The ORAL study and expanded black box warning
15:07 – Newer JAKS and Black Box inheritance
17:00 – The new molecules
18:00 – How to present biologics vs JAKs (age + delivery)
21:10 – Women of childbearing years
27:00 – Legacy black box on mace events, PEs, and DVTs – who’s at risk?
30:44 – Cancer and risk
32:10 – Patients at risk for serious infections
35:27 – JAKs and vaccinations
38:47 – Dosing adjustments
46:20 – Final thoughts on biologics and JAKs
